INTRODUCTION
Rare diseases affecting development, beyond their medical importance, offer us a unique opportunity to identify key genes involved in development and pathology. Wolf-Hirschhorn syndrome (WHS) is caused by the heterozygous loss of material in chromosome 4p arm (Battaglia et al., 2011 (Battaglia et al., , 2015 . Patients suffer from serious problems, including immunodeficiency, seizures, developmental delay, and mental retardation. The increased susceptibility to infections is a major cause of morbidity and mortality among WHS patients (Hanley-Lopez et al., 1998) . The heterozygous loss of the Wolf-Hirschhorn Syndrome candidate 1 gene (WHSC1, also known as MMSET and NSD2) has been postulated to be the main responsible for the malformations and the immune deficiencies (Bergemann et al., 2005) . WHSC1 is also involved in other pathologies affecting B lymphocytes, like multiple myeloma (Chesi et al., 1998; Stec et al., 1998) and childhood B cell acute lymphoblastic leukemias (Huether et al., 2014; Jaffe et al., 2013) . Furthermore, it belongs to the protein family of nuclear SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain (NSD) proteins, whose other members are also involved in developmental and tumoral pathologies (Morishita and di Luccio, 2011) . The WHSC1 protein contains a SET domain that confers it with histone-methyltransferase activity (Marango et al., 2008; Stec et al., 1998) . Its most important in vivo activity is to mediate H3K36 mono-and di-methylation (Kuo et al., 2011) , therefore acting as an epigenetic regulator (Kuo et al., 2011) . Methylation at H3K36 has been associated with regulation of transcription, splicing, DNA replication, and DNA repair (Wagner and Carpenter, 2012) . So far, a specific role for WHSC1 in the immune defects associated with WHS has not been proven, and, in general, the functions of the members of the NSD family in normal hematopoiesis have not been investigated, even though they are recurrently involved in hematopoietic malignancies (Hu and Shilatifard, 2016) . Here, we present in vivo genetic evidence showing that Whsc1 deficiency impairs normal hematopoietic development at several stages and lineages and particularly affects B cell differentiation and mature B cell function. These findings reveal the role of Whsc1 as a player in hematopoietic development and also indicate that many of the immune defects associated with WHS can be directly attributed to reduced levels of Whsc1. 
RESULTS

Lymphoid Differentiation Is Impaired in Whsc1
Heterozygous Mice Since WHS patients lack only one copy of the WHSC1 gene, we first studied hematopoietic development in heterozygous mice (Nimura et al., 2009 ). We could not identify any major hematopoietic changes in Whsc1 +/À mice at 6 months of age ( Figure S1A ). However, in Whsc1 +/À mice older than 15 months, a significant decrease in the percentages of B and T lymphocytes ( Figure 1A ) suggested a progressive defect in the long-term maintenance of the lymphoid compartment.
Competitive bone marrow transplantation (BMT) experiments were performed injecting wild-type (WT) (Ly5.1 + ) and Whsc1 +/À (Ly5.2 + ) cells in a 1:1 ratio into lethally irradiated Rag1 À/À mice ( Figure 1B ). In this competitive setting, the developmental defect of Whsc1 +/À B and T lymphocytes could be appreciated at an early stage ( Figure 1B ), since they can only contribute to $20% of the total lymphocytes in peripheral blood (PB). By contrast, the myeloid compartment is maintained at the initial 50:50 ratio, suggesting that its development is not, or only slightly, affected. In order to determine if the Whsc1 +/À lymphocyte defects could be counterbalanced by increasing their proportion in the mix, injections were performed at a 1:4 WT:Whsc1 +/À cell ratio ( Figure S1B ). This resulted in a compensating recovery of the lymphocyte chimerism to a 50:50 ratio. Once more, the myeloid ratios recapitulated those of the original injection ratio. Full necropsy of 1:1-ratio-injected animals (Figures 1C and S1C) showed that Whsc1 +/À LSK (lineage-negative, Sca1-positive, cKit-positive) hematopoietic stem/progenitor cells (HSPCs) and common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs) in the bone marrow (BM) were present at the original 50:50 ratio of injection, like myeloid cells ( Figure S1C ). However, the Whsc1 +/À B cell compartments beyond pro-B cells showed a gradual decrease, with the latest stages of B cell development being present only at a 20% ratio, like in the PB ( Figure 1C) . Therefore, the loss of one copy of Whsc1 leads to an impairment in lymphoid development that, under normal conditions, only manifests as the mice get older.
Whsc1 Is Required for Normal Hematopoietic Development
Given that Whsc1 À/À mice die at late gestational stages or in perinatal day 0 (Nimura et al., 2009) , in order to study the development of a full Whsc1 À/À hematopoietic system, we performed embryo fetal liver (FL) transplants. Whsc1 À/À cells could give rise to all the main types of hematopoietic cells ( Figure S2 ). Therefore, Whsc1 is not strictly essential for the development of any of the hematopoietic lineages. However, there were differences in the reconstitutive capacity of Whsc1 À/À cells. First, a kinetic delay could be seen in the repopulation of PB ( Figure 1D ), mainly due to the 3-fold reduction in the percentages of B220 + cells ( Figure 1E ). Automatic hematic analysis (Figures 1F and S2) confirmed that this 3-fold reduction was also occurring in the absolute numbers of lymphocytes. Fluorescence-activated cell sorting (FACS) analysis showed consistent alterations in different hematopoietic compartments ( Figures S3A and 1G) ; indeed, although total BM cellularity was not affected ( Figure 1H ), total B cell numbers were 5-fold reduced in the BM 1G ). This was confirmed by the more than 2-fold reduction in the percentages and absolute numbers of B cells in the spleen (Figures 1G and 1H) . T cell numbers were also decreased in the absence of Whsc1 ( Figure 1G ). In the spleen, there was a strong increase in the percentages of erythroblasts (Figures S3A and 1G) , suggesting the presence of extramedullary erythropoiesis. Finally, these alterations also led to a reduction of total cellularity in the spleen of Whsc1
-reconstituted animals ( Figure 1H ). (Figure 2A ). New competitive FLTs were performed in ratios 1:2 or 1:5 (data not shown) and 1:20 (Figure S1D ). At this last ratio, Whsc1 À/À myeloid cells could be found in the blood at an average ratio of 40% and B cells at $5%. 3 months after the 1:20 transplant, 45% of the LSK population in the BM ( Figure 2B ) was Whsc1
Whsc1
. The myeloid compartment was present in the same LSK range ( Figure S1E Figure 3A) shows that Whsc1 Figure 1A ) and by the clear impairment in B cell development beyond pro-B cells in secondary Whsc1 À/À recipients ( Figure S3C ). This reduction in B cell numbers was more dramatic in tertiary recipients ( Figure 3C ). Additionally, the effects of the lack of Whsc1 in erythropoiesis in the longterm can already be seen in secondary recipients by hematic counting, which shows reductions in hemoglobin, hematocrit, and platelets ( Figure S3B ). All of these effects indicate an impairment in the repopulation capacity of Whsc1 À/À hematopoietic stem cells (HSCs). Indeed, when mice with a 1:1 Whsc1
:WT mixture were examined a very short time after reconstitution (2, 4, 7, 15, and 30 days; Figure 3E ), Whsc1 À/À LSK cells and their descendants were quickly outcompeted. Furthermore, FACS analysis of primary recipients ( Figure 3D ) showed a significant, Whsc1 dose-dependent reduction in the percentages of LSK cells in the BM.
To discard the idea that the developmental defects we found might be due to transplantation-induced hematopoietic stress, FL, fetal spleen, and fetal thymi of Whsc1 À/À E18-E21 embryos were analyzed ( Figure S3D ). In the fetal spleen, the percentage of CD19 + cells was reduced by half in Whsc1 À/À embryos and, in the fetal thymus, a severe reduction in the percentage of CD4-SP cells was evident in heterozygous embryos and dramatic in Whsc1 À/À embryos. Similar results were found in FL (data not shown), supporting the true nature of the developmental defects identified in our transplantation studies. Figure 4D ). All of these results show that in vivo, in lymphocytes in a genetic model, Whsc1 is required for an efficient CSR to most of the isotypes, providing a model that really recapitulates one of the most serious complications faced by WHS patients. Since CSR is linked to cellular proliferation, ex vivo competitive assays were carried out after labeling the cells with CellTrace in order to follow the different cycles of division. The contribution of Whsc1 À/À cells was strongly reduced in all generations, and at the end, it accounted for a very reduced percentage (Figures 4E, 4F, and S4), and absolute number ( Figure 4G ) of cells, supporting the existence of a proliferative impairment in Whsc1 À/À cells.
Class Switch Recombination Efficiency Is Reduced in
FACS analysis also showed ( Figure 4H ) increased levels of apoptosis in stimulated Whsc1 À/À B cells.
Cell-Cycle Alterations in Whsc1 À/À B Cells and HSPCs
We performed cell-cycle analysis in the presence of bromodeoxyuridine (BrdU) during the CSR reaction. After 72 hr under stimulation, in all the different cell generations, there was a 3-fold increase in the number of cells in the S phase of the cell cycle in Whsc1 À/À B cells (Figures 5A and S5A) . To investigate whether this alteration was also present in vivo at the other developmental points where we had found that the absence of Whsc1 led to important malfunctions, we performed in vivo BrdU labeling. The results showed that in the BM, both B cells at all of the different developmental stages (Figures 5B and 5F) and LSK cells ( Figure 5C ) showed an increased number of BrdU + S phase cells, while Whsc1 À/À myeloid cells did not present any alteration ( Figure 5B ).
It has been reported that changes in the pattern of methylation at H3K36 can affect DNA repair (Wagner and Carpenter, 2012) , and WHSC1 has been associated with DNA damage repair (Evans et al., 2016; Hajdu et al., 2011; Shah et al., 2016) . We studied the levels of gH2AX, a well-known indicator of the existence of broken DNA ends. In the context of the CSR reaction ( Figures 5D, S5B , and S5C), we could see progressively increased levels of gH2AX during the successive generations in Whsc1 À/À cells, and this correlates with the accumulation of cells in S phase. Furthermore, also in vivo, a slight elevation in gH2AX levels can be appreciated in Whsc1 À/À total B cells in the BM, especially when compared with Whsc1 À/À myeloid cells that, once more, seem to be unaffected ( Figure 5E ). Also, a similar increase in gH2AX levels could be detected in BM Whsc1 À/À LSK cells ( Figure 5E ). These same results could be found in a totally different cell type, Whsc1 À/À mouse embryo fibroblasts (MEFs), which also presented a very compromised proliferative capacity ( Figure 5G ) and severe impairment in the downregulation of gH2AX levels after DNA damage (gamma irradiation instead of CSR, in this case) ( Figure 5H ). Tables S1, S2 , and S3). The results demonstrate the existence of severe defects at many key levels of cellular biology. First, a basic differential gene expression analysis showed that there are several developmental genes deregulated in the absence of Whsc1, like the genes of the Hoxa cluster ( Figure S6A ; Tables S1 and S2 ). These developmental genes, although of great importance to the morphogenetic pathways affected in WHS patients, do not explain the B cell phenotypes that we have described. However, using pathway analysis, we observed that many key processes, such as the cell cycle, splicing, ribosome synthesis, DNA replication, or DNA repair, are very significantly altered in proliferating Whsc1 À/À B cells ( Figure 6A ; Table S3 ). Functional analysis using gene set enrichment analysis (GSEA) (Figures 6B and S6B) confirmed these findings. Indeed, although B cell-specific pathways are also affected (Figures 6B and S6B, ''BCR signaling''), and this could explain some aspects of the developmental B cell impairment, the downregulation of ribosomal proteins, the upregulation of the components of the spliceosome or of cell cycle genes (Figures 6A and 6B) are directly related to all the cellular phenotypes described. In concordance with the accumulation of gH2AX, a very strong deregulation of the genes involved in DNA repair could be seen ( Figures 6B and S6B ). Among them, there was an upregulation of the Fanconi anemia pathway, which is involved in the repair of DNA damage associated with DNA replication (Kais et al., 2016) . In fact, one of the most significantly altered pathways was the one regulating DNA replication (Figures 6B and S6B), therefore pointing toward this process as a potential trigger of the abnormal proliferative behavior of Whsc1 À/À cells.
Absence of Whsc1 Leads to Increased DNA Replicative Stress in GC B Cells
In some cell lines, Whsc1 is associated with DNA damage repair (Evans et al., 2016; Hajdu et al., 2011; Shah et al., 2016) . Also, cell lines derived from WHS patients present delayed cell-cycle progression and impaired DNA replication (Kerzendorfer et al., 2012) , but which gene is responsible for this phenotype among the many genes lost in WHS is not yet clear. It has been shown that correct H3K36me3 patterns are required to prevent replicative stress in cancer cells lines (Kanu et al., 2015) , and H3K36 demethylation has been shown to control proliferation, the cell cycle, and hematopoietic development (Andricovich et al., 2016; He et al., 2008) . Therefore, as suggested by the RNAseq results, we decided to test in our in vivo model whether the proliferative impairment could be due to increased levels of DNA replicative stress. We performed DNA fiber analysis (Flach et al., 2014) in Whsc1 À/À MEFs and stimulated B cells. There was a reduction in both the fork rate and the inter-origin distances in the absence of Whsc1 ( Figure 6C ), confirming an impairment in the advancement of the replication fork, coupled with the activation of new dormant origins. We also cultured cells in the presence of increasing concentrations of the DNA replication inhibitor aphidicolin ( Figures S5D and S5E ). Whsc1 À/À cells were more affected by aphidicolin than WT cells ( Figure S5D ), but, more significantly, cell cycle analysis showed that in the presence of aphidicolin, Whsc1 À/À B cells could not correctly exit S phase ( Figure S5E ), presenting a prolonged S phase without properly entering G2/M. These results confirm that replication stress is the main molecular mechanism behind proliferative impairment in the absence of Whsc1.
Specification and Commitment to the B Cell Lineage Are Strongly Impaired in Whsc1 À/À B Cell Progenitors
In order to identify whether the impairment in the pro-B to pre-B cell transition was due to the same molecular mechanism, we sorted BM pro-B cells and performed RNA-seq followed by differential gene expression and GSEA. We found that Whsc1
pro-B cells share some of the defects found in GC B cells but with different severity, and, more significantly, they also present pro-B cell stage-specific transcriptional defects (Tables S4, S5 , and S6; Figures 7 and S7). Indeed, Whsc1 À/À pro-B cells also present significant alterations in DNA repair, DNA replication, and cell cycle gene sets ( Figures 7A and S7A ) and downregulation of genes involved in nucleosome and chromatin organization ( Figures 7A and S7A ). Since there was no statistically significant difference in the percentage of cells in S phase between WT and Whsc1 À/À BM pro-B cells ( Figure 5F ), these RNA-seq differences most likely reflect intrinsic, cell-specific differences between the two genotypes; there was a significant downregulation of key early B cell developmental genes (Table S5) , including Ikzf3, Tcf3/E2a, Ebf1, Pax5, Rag1, Rag2, Il7r, and Foxo1 , and this was particularly important in the case of Ebf1 (16-fold downregulated in Whsc1 À/À cells) and Pax5 (9.5-fold downregulated).
Since these genes are key regulators of the specification and commitment to the B cell lineage (Cobaleda et al., 2007) , we generated specific genes sets with the most relevant of their published targets (Pongubala et al., 2008; Revilla-I-Domingo et al., 2012; Treiber et al., 2010) and evaluated them by GSEA ( Figures 7B, 7C , and S7B). The results showed a strong downregulation of a significant majority of the Ebf1-and Pax5-upregulated target genes in Whsc1 À/À pro-B cells, affecting most of the biological processes necessary for the specification and commitment of progenitors to the B cell lineage (Cobaleda et al., 2007) . These data therefore correlate with the developmental block at this early phase of B cell differentiation and show that Whsc1 participates in different mechanisms that control differentiation and function at several stages of B cell life.
DISCUSSION
An increased susceptibility to infections is one of the main pathological characteristics affecting WHS patients, and the molecular basis for this immunodeficiency is so far unknown. (Sonoda et al., 1997) . However, this, by itself, was not enough to overcome the block ( Figure 7D ), confirming its dependence on many deficient signaling molecules and B cellspecific factors beyond immunoglobulin rearrangements. In summary, Whsc1 À/À cells can generate CLPs, pro-B cells, and later B cell stages too, but they do not do this efficiently; in the absence of competition, impairment exists, but it is leaky and allows for the generation of mature B cells, although with a much reduced efficiency. Therefore, B cell specification and commitment can take place in the absence of Whsc1, but these processes are seriously compromised and become insufficient when challenged in any way. Regarding later stages of B cell development, we could also show that there is an impairment in the CSR reaction that is dose dependent in relation to the absence of the Whsc1 alleles. This is related to an aberrant proliferation of Whsc1-deficient cells, which showed a 3-fold increase in the percentage of cells in S phase, coupled with an accumulation of DNA damage. Whsc1-deficient cells have large deregulations of gene sets involved in key biological processes, among them the genes involved in DNA repair and DNA replication. They also show a significantly decreased fork rate counteracted by local increases in origin density, suggesting that a higher frequency of stalled forks induces compensatory activation of dormant origins and triggers a DNA damage response (Maya-Mendoza et al., 2009) . The fact that the Fanconi anemia (FA) pathway (responsible for repairing DNA as a response of replication stress; Kais et al., 2016) is significantly altered further supports this idea. This replicative stress leads to the accumulation of DNA damage, as indicated by increased gH2AX levels; however, this does not result in increased numbers of chromosomal aberrations as measured by DNA FISH on the immunoglobulin locus (C.C. and J.A.K., unpublished data). There is also an accumulation of (H) Impaired DNA damage repair in Whsc1 À/À MEFs. WT and Whsc1 À/À MEFs were irradiated with 5 Gy and gH2AX levels were measured after 1 and 5 hr.
Whsc1
À/À MEFs cannot efficiently remove gamma-irradiation-induced gH2AX accumulation, while levels of gH2AX have reverted to normal in WT MEFs within 5 hr after exposure. One representative analysis is shown out of three independent experiments with a total of 12 MEF preparations (6 Whsc1 +/+ and 6 Whsc1 À/À embryos). See also Figure S5 . Whsc1-deficient apoptotic cells ( Figure 4H ), suggesting that those cells that cannot cope with the replication stress die and, in the surviving cells, the increased DNA repair mechanisms, together with the increased numbers of replication origins and an elongated S phase, allow them to correctly finish the cell cycle, although the global fitness of the population is severely affected, as shown by all the different competition experiments. Additionally, one of the cellular components most affected by replicative stress is the ribosome, both at the rRNA and protein levels (Golomb et al., 2014) , and stimulated Whsc1-deficient cells show a massive downregulation of the expression of integral ribosomal proteins, most likely as a reflection of this fact. According to the methyltransferase activity of Whsc1, it has been demonstrated in different tumor-related experimental settings that alteration of WHSC1 activity levels leads to parallel global changes in the patterns of H3K36 methylation (García-Carpizo et al., 2016; Kuo et al., 2011; Oyer et al., 2014; Popovic et al., 2014) . In our Whsc1
À/À mouse model, it has already been shown by western blot and immunohistochemistry that the levels of H3K36 methylation are reduced in Whsc1 knockout (KO) cells (Nimura et al., 2009; Sarai et al., 2013) . Therefore, the changes in gene expression revealed by RNA-seq experiments are most likely downstream of changes in H3K36 methylation patterns and include indirect effects of an altered epigenetic landscape. In the context of B cell differentiation, the pro-B to pre-B transition and the germinal center reaction are the two stages corresponding to the maximum peaks of expression of Whsc1 in hematopoiesis (http://www.immgen.org; Heng and Painter, 2008) , suggesting that the high levels of Whsc1 expression makes these cells particularly vulnerable to the loss of this gene. Conversely, comparative RNA-seq analysis of gene expression in non-proliferative, ex-vivo-sorted, resting lymph node B cells (data not shown; two WT versus four KO samples) did not show any significant changes in the pathways that were greatly altered in proliferative CSR B cells or pro-B cells, only in some of the morphogenetic developmental genes. We also found the existence of a stem cell functional defect in the absence of Whsc1. First, there was a dose-dependent decrease in the percentage of LSK cells in the absence of Whsc1 ( Figure 3D ). Since the total BM cellularity was relatively constant between WT and Whsc1 À/À animals ( Figure 1H Figure 5G ) and have increased DNA replicative stress ( Figure 6C ) and impaired DNA repair ( Figure 5H ). Finally, the results from short-term analysis of mice transplanted in a 1: Altogether, our results show that Whsc1 is involved in hematopoietic development at several stages and implicate different cellular lineages. Furthermore, Whsc1 participates in the regulation of different molecular mechanisms throughout these different stages and cell types, from HSC function to B cell lineage specification and commitment, fitness, and cellular proliferation. Our results highlight Whsc1 as a player in the control of hematopoietic and especially B cell development, and they also indicate that the immune defects associated with WHS can be directly attributed to reduced levels of Whsc1. These findings provide a framework for the understanding, prognosis, and potential future treatment of immunodeficiency in WHS.
EXPERIMENTAL PROCEDURES Mice
The following mice were maintained in the C57BL/6 background and, when required, genotyped as described previously: Whsc1 À/À (Nimura et al., Mombaerts et al., 1992) , and B6.SJL-PtprcaPep3b/BoyJ. All mice were housed in a specific-pathogen-free (SPF) barrier facility. All experimental procedures conducted on mice were approved by the CBMSO's Institutional and Spanish Regional Committees on Ethics of animal research. Mice with the indicated genotypes were included in the study without any further preselection or formal randomization and with balanced numbers from both genders; we used age-matched mice. Investigators were not blinded to genotype group allocations. All mice were maintained in C57BL/6J background.
FACS Analysis and Sorting Purification
Contaminating red blood cells were lysed using ACK Lysing Buffer. The remaining cells were washed in FACS buffer (13 PBS with 2% heat-inactivated fetal bovine serum [HI-FBS] Proliferation, Damage, and Cell-Cycle Analysis The Apoptosis, DNA Damage and Cell proliferation Kit (catalog number 562253, BD Pharmingen) was used to assess the proliferative capacity of the cells, as well as cell-cycle dynamics and DNA damage accumulation. Anti-BrdU-FITC or Anti-BrdU-APC versus 7AAD were used to study the cell cycle, and the CellTrace Violet Cell Proliferation Kit (catalog number C34557, Invitrogen) was used to monitor cell proliferation. CountBright Absolute Counting Beads for flow cytometry (MP 36950, Molecular Probes, Invitrogen) were used to measure absolute cell yield in culture.
CSR Assays
Mouse primary B cells were purified from the spleens of the indicated strains of mice by immunomagnetic depletion with anti-CD43 beads (Miltenyi Biotec) and cultured in 50 mM 2-b-mercaptoethanol (Invitrogen), 10 mM HEPES (Invitrogen), 1 mM glutamine, antibiotics, non-essential amino acids, and 10% HI-FBS RPMI medium supplemented with (1) 25 mg/mL LPS (SigmaAldrich), (2) 25 mg/mL LPS and 20 ng/mL interleukin 4 (IL-4) (PeproTech), (3) 25 mg/mL LPS and 2 ng/mL TGF-Beta1 (R&D Systems), or (4) 20 ng/mL IL-4 (PeproTech) and 1 mg/mL anti-CD40 (eBioscience) or non-supplemented (only growth medium). Cells were counted using a handheld automated cell counter (Scepter, 40 mm tips), and the CellTrace Violet Cell Proliferation Kit was used as proliferation tracer.
RNA Extraction
Proliferating B cells were obtained by in vitro LPS stimulation over a 72-hr period as previously described. BM pro-B cells were sorted as previously described. Sorting strategy and purity are shown in Figure S7D . RNA was extracted using a commercial TRIzol reagent (catalog number 15596-026, Life Technologies, Gibco) according to the manufacturer's recommendations. Chemical quality was measured with a Nanodrop 1000 Spectrophotometer (Thermo Scientific), and integrity was confirmed using the Agilent 2100 Bioanalyzer. Libraries for RNA-seq were prepared as indicated in Supplemental Experimental Procedures.
DNA Fiber Spread
Replication track analyses were performed as described previously (Flach et al., 2014) , with only minor modifications. MEFs were traced at exponential growth during their third passage, and proliferating B cells were obtained after 48 hr of in vitro culture under LPS stimulation. Both cell types were incubated for 20 min with each thymidine analog (first 5-Chloro-2 0 -deoxyuridine [CIdU] and then 5-Iodo-2 0 -deoxyuridine [IdU] ) and washed three times with warm 13 PBS (37 C). Spreading buffer incubation was for 6 min, primary antibody incubation timing was extended to overnight, and secondary antibody incubation was 2 hr. Tracks were imaged on a fluorescence resonance energy transfer (FRET) Zeiss microscope coupled to a Hamamatsu camera. All pictures were taken at 403 magnification. Fork rate (FR) and inter origin distance (IOD) were calculated based on the length of the IdU tracks measured using ImageJ software and the already published formulas fork rate (kb min À1 ) = (2.59 (kb mm À1 ) 3 length (mm)/ pulse time (min)) and IOD (kb) = length between two contiguous origins (mm). When aphidicolin was used, it was added at 1 mg/mL with the second pulse of thymidine analog (IdU).
Statistical Analysis
Exact sample sizes and statistical tests used for comparisons are indicated in each figure. Kaplan-Meier survival curves were created and analyzed using Prism (GraphPad Software), which used the log-rank test to calculate significance. Samples were allocated to their experimental groups according to their predetermined type (i.e., mouse genotype), and, therefore, there was no randomization. Sample sizes chosen are indicated in the individual figure legends and were not based on formal power calculations to detect pre-specified effect sizes. Data analysis was not blinded.
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